INFU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
InfuSystem Holdings Inc (INFU) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, bullish technical indicators, positive analyst sentiment, and lack of significant negative catalysts make it a solid choice for a long-term investment.
The technical indicators for INFU are generally bullish. The MACD is above 0 and positively contracting, indicating a potential upward trend. The RSI is neutral at 53.651, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels suggest the stock is trading near its pivot point, with room for upward movement.
Strong financial performance in Q4 2025, with revenue up 7.04% YoY, net income up 118.22% YoY, and EPS up 150% YoY.
Positive analyst sentiment with raised price targets and 'Buy' ratings.
Bullish technical indicators suggesting potential upward price movement.
Hedge funds are selling, with a significant increase in selling activity (1158.53%).
Lack of recent news or event-driven catalysts.
No recent congress trading data to support insider confidence.
In Q4 2025, INFU demonstrated strong financial growth: Revenue increased by 7.04% YoY to $36.23M, net income surged by 118.22% YoY to $2.036M, EPS grew by 150% YoY to $0.1, and gross margin improved by 5.16% YoY to 55.82%.
Analysts are bullish on INFU. Lake Street raised the price target to $17.50 (from $15) and maintained a 'Buy' rating, citing confidence in management's decisions and high ROIC. Roth Capital raised the price target to $15 (from $14), highlighting above-consensus Q4 results and improved treatment volumes in oncology and wound care divisions.
